logo
New Israeli website gets down to the roots of nature's medicine chest

New Israeli website gets down to the roots of nature's medicine chest

Yahooa day ago
For the first time, an open-access website called Florapal serves as a botanical encyclopedia of plants native to the Holy Land.
Plants – their leaves, fruit, and other parts – have served as mankind's medicine cabinet for thousands of years. For most of the millennia, there were no pills or synthetic medicines; instead, healers recognized the benefits of plants that grew nearby to treat a wide variety of diseases and conditions, from abdominal pain, arthritis, kidney problems, memory loss, and asthma to gout, heart palpitations, infertility, infections, and cancer.
Numerous plants that have grown in this region can be found in other parts of the world, too, but this area is particularly rich in species, some unique only to Israel, with some 2,700 different types of plants, trees, and shrubs growing in a wide variety of terrain, including Mediterranean, mountainous, and desert areas.
The fact that they were used does not guarantee that they are all effective or even that they are not harmful, but many could be synthesized and turned into contemporary pharmaceuticals if proven safe and potent.
The Holy Land's botanical encyclopedia
Now, for the first time, an open-access website called Florapal (at florapal.org/) serves as a botanical encyclopedia of plants native to the Holy Land – an area botanically known as 'Flora Palaestina' – a term first used by Linnaeus in the 18th century to describe plants native to this region today. It comprises the State of Israel, the Palestinian Authority (Judea and Samaria or West Bank), Gaza, and western Jordan.
The site itself describes 316 native species and over 2,000 uses, including medical as well as non-medical applications such as food, spice, soap, dye, beverages, cosmetics, perfume, cleaning products, preservatives, veterinary care, agriculture, poison, and insect repellents. Ceremonial and ritual uses that included magical protection from the 'evil eye' that was offered by traditional healers are also included.
An analysis of data in the ethnobotanical website of Flora Palaestina reflects some interesting trends of changing patterns of plant use in this region during the mid-20th to the 21st century. The term Flora Palaestina, however, has nothing to do with politics, Palestinians, or Philistines. It was first used by Carl Linnaeus, the 18th-century Swedish biologist and physician who is famous for his work in taxonomy – the science of identifying, naming, and classifying organisms (plants, animals, bacteria, fungi, and more). In the 2nd century, Roman Emperor Hadrian renamed the territory of Judea as Palaestina as part of an effort to suppress Jewish nationalism after the Bar Kochba revolt and erase the memory of the Jewish presence there.
Florapal – an English-language website but with colloquial plant common names also provided in Hebrew and Arabic – is the first of its kind. Containing a search engine and photographs, it was created by combining previously unpublished surveys of plant use by Jewish and Arab populations in this region (between 1950 and 1979) with later surveys among the Arab population of the West Bank and Gaza (1996-2016).
The website provides for the first time in English a systematic and detailed description of the traditional uses of over 316 species of Flora Palaestina; the contents are 'a rich legacy that is rapidly being lost as societies develop and modernize,' said Dr. Sarah Sallon, who established 30 years ago and continues to run the Natural Medicine Research Center (NMRC) of the Hadassah Medical Organization in Jerusalem who trained as a physician and worked for many years as a pediatric gastroenterology specialist.
She initiated the Florapal project and headed the team that established the website. 'Sadly, according to recent surveys, some 400 species are now on the 'Red List' of endangered species, while in the West Bank, about 5% are critically endangered,' she said in an extensive interview with The Jerusalem Post.
SHE AND her team, together with Palestinian researchers at BERC (The Biodiversity and Environmental Research Center in Til Nablus), have just published a peer-reviewed article about the website in the journal Ethnobotany Research and Applications titled 'Florapal an ethnobotanical website of Flora Palaestina reflects changing patterns of plant use in this region during the mid-20th to 21st century.' The detailed article will undoubtedly arouse interest among professionals and others who care about botany and this region.
Information for the Florapal website is based on combining two important ethnobotanical resources. The first is the previously unpublished ethnobotanical surveys (in Hebrew) of the late Dr. David Zaitschek of the Hebrew University's Faculty of Medicine, describing plant use amongst Jewish and Arab populations in the mid-20th century. A botanist and bacteriologist, Zaitschek headed the botanical laboratories at the university's botany department. The archive situated in his lab consisted of a cardex containing several thousand alphabetically indexed, handwritten notes he made in Hebrew.
The second contribution is based on surveys of plant use carried out by BERC in the Arab population of the West Bank and Gaza in the early 2000s.
When reaching Florapal, one sees on the screen a statement to which all users have to agree – that those involved don't endorse or recommend the use of any species or plant preparations, and that the information 'is not a substitute for medical advice or treatment and the authors of this site do not purport to provide any medical advice... They are used only by the authors to suggest potential or possible activity and are not intended as scientific evidence nor a recommendation for a particular remedy or use. Always seek professional advice from your physician before consuming any plant for medicinal or other purposes.'
Today, hospitals and clinics have replaced healers, while village economies once dependent on local plant resources have largely been replaced by manufactured and imported goods. As a result, said Sallon, 'a rich legacy of plant use acquired by Jews and Arabs over hundreds of years is rapidly being lost.'
The current study is part of a larger project between Israeli and Palestinian researchers supported by USAID-MERC (United States Agency for International Development-Middle East Regional Cooperation Program). Her partners included Dr. Mohammed Ali-Shtayeh, director, and his staff at BERC; Dr Ori Fragman-Sapir of the Jerusalem Botanical Gardens; and Dr Elaine Solowey of the Center for Sustainable Agriculture at Kibbutz Ketura in the Arava.
The Talmud, Mishna, and Midrashic sources provided major insights into the economic, cultural, and historical uses of local species in antiquity. Over the following centuries, traditional knowledge was passed down verbally from generation to generation within local Arab communities and by Jewish immigrants to the region from Middle Eastern countries that share many of the same species. The plants were also used as spices, dyes, perfumes, and cosmetics, in rope- and basket-making and clothing, and as raw materials for building.
The rich diversity of Flora Palaestina
BY THE 20th century, comprehensive systematic studies on Flora Palaestina were carried out by the famous Israeli botanists Prof. Michael Zohary and Prof. Naomi Feinbrun-Dothan, based mostly on plants deposited in the herbarium of the Hebrew University. More recently, quantitative assessments on plant use in the West Bank and Gaza documented by Ali-Shtayeh and his team have been published in peer-reviewed journals.
Zohary wrote in 1973 that 'the rich diversity of Flora Palaestina has been associated with this region`s varied topography, climate, and soil, including broad expanses of alluvial soils with rich weed flora and abundant multi-regional types; Mediterranean coast with typical sand dune vegetation; Judean mountains containing Mediterranean forest and maquis [shrub] vegetation; Judean desert with Irano-Turanian vegetation; a desert landscape with tropical savannah, salines, and rock-floored 'hammadas' [a type of desert landscape consisting of high, barren, hard basalt plateaus where most sand has been removed.'
'The website draws attention to an important historical legacy, the urgent need for conservation of many of these species, their continuing importance to a healthy environment and a potential source of novel foods, natural products and new drugs,' Sallon stressed.
'When we analyzed the data in the website ' Sallon continued, 'we found that 50 species are still being used for the same conditions that were utilized seven decades ago,' 'These include diarrhea and dysentery, as well as diabetes, arthritis, kidney stones, coughs, cold, eye and ear infections, high blood pressure, improving memory, and cancer. Newer uses, however, that were not shown in the earlier Zaitschek surveys but appeared in the later BERC survey, showed some plants now being used for conditions like weight loss and high cholesterol, problems increasingly common in the 21st century. Many uses also relate to very well-known flora, for example, the olive tree that can be used not only to make olive oil but also to treat many medical problems, Sallon added.
'Based on these fascinating traditional uses, we have used these plants to previously study and publish with scientists at Hadassah and the Hebrew University Medical Faculty, how effective they are in the lab, including against conditions like cancer and Alzheimer's disease. One must be careful, however, as some plants or parts of them can be really toxic, she added. Unripe almonds, for example, can be very dangerous, while parts of the rhubarb plant should not be consumed.
She concluded that 'Florapal is an important educational resource that preserves the historical legacy of plant use in this region, contributing to their conservation, research, and development.'
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Do Comorbidities Shape MS Outcomes?
Do Comorbidities Shape MS Outcomes?

Medscape

time5 hours ago

  • Medscape

Do Comorbidities Shape MS Outcomes?

This transcript has been edited for clarity. Thanks so much for the opportunity to talk to you today about the effects of comorbidity in people living with multiple sclerosis (MS). My name is Ruth Ann Marrie. I'm a professor of medicine and community health and epidemiology, and the Multiple Sclerosis Clinical Research Chair at Dalhousie University. Today, I'd like to talk to you about what comorbidities often affect people with MS, how often they occur, and the effects of comorbidity on MS-related outcomes. When we talk about comorbidity, we're referring to the total burden of illness other than the specific disease of interest. In our case, MS is the disease of interest, so the comorbidities could include diabetes or hypertension, for example. We exclude from this definition complications that are secondary to MS, like urinary tract infections due to neurogenic bladder. Why? Well, it has importance in terms of thinking about the clinical target. Common Comorbidities in MS: What Can We Learn? Why, more broadly, are we interested in studying comorbidity? Comorbidity may help us to better explain the difference in outcomes between people with MS; we know outcomes are highly heterogeneous. It may help us better prognosticate and make treatment decisions for people with MS. It may also give us insights into the pathogenesis of MS. If we found that diabetes was associated with worse outcomes, we might think about how diabetes affects the brain in terms of its effects on the endothelium, for example, or the role of insulin receptors, and that might then lead to new treatment avenues. What do we know about comorbidity in MS at the present time? We know it's present throughout the disease course, and people with MS actually have a higher burden of some comorbidities even before they present with their first clinical symptoms. We've seen that people with MS have an increased incidence of psychiatric disorders, for instance, five to 10 years before their first clinical presentation. At the time of an MS diagnosis, the most common conditions that we see are depression, hypertension, chronic lung disease (particularly asthma), and anxiety disorders. Depending on the age of the individual with MS at the time of their initial presentation, the prevalence of those conditions may exceed 15%. Overall, we think at least 1 in 4 people with MS have a comorbid condition at diagnosis. If we take a random snapshot of any prevalent MS population, then the most common comorbidities we see are similar to those that we see at diagnosis, with depression and anxiety disorders as well as hypertension being prevalent. Hyperlipidemia and irritable bowel syndrome are also present. An important issue is how the prevalence of those conditions evolves over the course of MS. About 20%-30% of people with MS are going to have depression or an anxiety disorder at any given point in their disease course. In contrast, conditions like hypertension, hyperlipidemia, and diabetes are going to increase in prevalence with age. This means people are typically going to have a much higher burden of comorbidity later in their disease course when it's already becoming more difficult to manage their MS, and they may be taking many symptomatic therapies. You might say, well, they're common and we have to worry about polypharmacy between managing the comorbidities and the symptoms of MS, but what's the actual impact on outcomes? Comorbidities and Disease Progression Well, there's been a large amount of work to show that cardiometabolic and psychiatric comorbidities affect multiple outcomes in MS, ranging from delays in the time from symptom onset to diagnosis, the severity of disability at diagnosis, the rapidity of disability progression and lifespan, and quality of life. I'm going to focus on a couple of those for today — specifically, relapses and disability progression. Multiple studies suggest that comorbidity influences relapse rates and the rate of disability worsening. One of the earliest studies was done at the State University of New York at Buffalo by Bianca Weinstock-Guttman and colleagues. It suggested that if you had dyslipidemia, you had faster disability progression and faster accrual of new hyperintense T2 lesions on MRI. Some subsequent studies — for instance, one done by Dr Kyla A. McKay and colleagues — found that among individuals with psychiatric comorbidity, their disability progressed faster. She [and her colleagues linked data from two Canadian clinical and population-based health administrative databases] and, using these datasets, followed over 2000 people for an average of about 10 years. For people who had a mood or anxiety disorder, they accrued nearly 0.3 more Expanded Disability Status Scale (EDSS) point per year than people without psychiatric comorbidity. You might think, well, that's not very much. When you consider that most people with a psychiatric disorder are going to face that long term, you think about that over a 10-year time horizon, that's the difference of about 3 EDSS points. That's the difference between mild and moderate disability, so it's quite substantial. Similar findings have been reported looking at physical comorbidities as well. There was a fairly recent study done by Dr Amber Salter, who is based at UT Southwestern, and colleagues, using meta-analysis of clinical trial datasets. It included 17 trials involving almost 17,000 people with MS. The advantage of this dataset is that people in clinical trials are followed very closely and rigorously, with frequent assessments. She and her colleagues identified comorbidities at the time of enrollment in the clinical trials, and 61% of participants in the trials had some evidence of disease activity, whether it was relapses, disability worsening, or new lesions on MRI. Individuals who had three or more comorbidities had a 14% increased rate of disease activity. Having two or more cardiometabolic comorbidities was associated with a 21% increased rate of any disease activity. When they looked at individual comorbidities, they found that depression and ischemic heart disease seemed to be the biggest driver of those effects. This is really important to think about when you look specifically at relapses. More comorbidities were associated with more relapses. They also found that more comorbidities were associated with faster disability worsening. This really points to the adverse impact of comorbidity on outcomes in MS. This is an example of a longitudinal design, rigorously assessed, so it reduces concerns about the concept of reverse causality — that is, that people with more severe MS may be more likely to accrue comorbidities because they're less physically active, they're not able to eat as well, and so on. The design doesn't fully mitigate that concern. There's another recent study, by Dr Kaarina Kowalec and colleagues, which tried to address this issue by using polygenic scores as an instrumental variable. Polygenic scores are basically weighted averages of all the variants that would be associated with a particular outcome — in this case, depression. The nice thing about using genes is that they are assigned to us at birth. MS couldn't cause those genes to be assigned. If we can show that the polygenic score for depression is associated with relapses and disability progression in the same way that having depression is, then we can remove that concern about reverse causality. In fact, the study findings suggest that's the case. When we put all of these kinds of findings together, they strongly suggest that there is an important role for comorbidities in influencing outcomes and that we really need to intensify our focus on preventing or mitigating those comorbidities as a means of improving outcomes in people with MS. A key question will be, 'What's the best way to do that?' Is it by simply treating these comorbidities the way we normally would, or do we need to treat them more aggressively? Does the type of intervention for those comorbidities matter in terms of achieving that goal of improving outcomes? I think we really need to begin to think about how to integrate these concepts into routine clinical practice. For that, guidelines and tools will be necessary to reach those goals. Thank you so much for your attention today.

Gaza war death toll surpasses 62,000, says Palestinian Health Ministry
Gaza war death toll surpasses 62,000, says Palestinian Health Ministry

Los Angeles Times

time6 hours ago

  • Los Angeles Times

Gaza war death toll surpasses 62,000, says Palestinian Health Ministry

CAIRO — The Palestinian Health Ministry said on Monday that more than 62,000 Palestinians have been killed in the 22-month war in Gaza. At least 60 people were killed in the past 24 hours, bringing the death toll from the Israel-Hamas war that started on Oct. 7, 2023, to 62,004. Another 156,230 have been wounded, it said. The Health Ministry said 1,965 people have been killed while seeking aid from aid convoys or killed close to aid distribution sites. At least seven Palestinians were killed attempting to access aid on Monday morning. The ministry, which doesn't distinguish between civilians and combatants in its count, is staffed by medical professionals. The United Nations and other independent experts view its figures as the most reliable count of casualties. Israel has disputed its figures, but hasn't provided its own account of casualties. The Palestinian Health Ministry said on Monday that more than 62,000 Palestinians have been killed in the 22-month Gaza war. At least 60 people were killed in the past 24 hours, bringing the death toll from the Israel-Hamas war that started on Oct. 7, 2023 to 62,004. Another 156,230 have been wounded, it said. The Health Ministry said 1,965 people were killed while seeking aid from aid convoys or killed close to aid distribution sites. At least seven Palestinians were killed attempting to access aid on Monday morning. Also on Monday, Egypt's top diplomat condemned Israel's plan to forcibly resettle Palestinians outside of Gaza and said the country is attempting to restart ceasefire negotiations along with Qatar. Mediators are 'exerting extensive efforts' to revive a U.S. proposal for a 60-day ceasefire during which the warring parties will negotiate an end to the war, Egyptian Foreign Minister Badr Abdelatty said on the Egyptian side of a crossing between Egypt and Gaza. He met there with Palestinian Prime Minister Mohammad Mustafa.

Reclaiming Innovation in Patient-Centered Care
Reclaiming Innovation in Patient-Centered Care

Medscape

time6 hours ago

  • Medscape

Reclaiming Innovation in Patient-Centered Care

Medscape 2050: The Future of Medicine Summary: In this wide-ranging, deeply thoughtful commentary, Professor Christina Pagel, professor of operational research at University College London, underscores why data and AI, while transformative, are not silver bullets for modern healthcare challenges. Drawing from decades of experience working directly with clinicians, Pagel illustrates how collaborative, multidisciplinary environments drive more meaningful innovation than technology alone. She cautions against overreliance on AI, noting its limitations in upstream determinants of health and long-term outcomes. Instead, Pagel champions a model of medicine that prioritizes well-being, long-term survival, and access to care — especially for populations often ignored by traditional metrics and research, such as women with chronic menstrual pain. From clean water access to systemic underinvestment in "unsexy" conditions, Pagel's insights invite a critical rethinking of how medicine should evolve: not by replacing human judgment with algorithms, but by strengthening the diverse human networks that define healthcare's most effective interventions. Key Takeaways:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store